Literature DB >> 20422266

Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer.

Sanjeev Banerjee1, Asfar S Azmi, Subhash Padhye, Marjit W Singh, Jubaraj B Baruah, Philip A Philip, Fazlul H Sarkar, Ramzi M Mohammad.   

Abstract

PURPOSE: Pancreatic cancer (PC) is one of the deadliest of all tumors. Previously, we were the first to show that Thymoquinone (TQ) derived from black seed (Nigella sativa) oil has anti-tumor activity against PC. However, the concentration of TQ required was considered to be high to show this efficacy. Therefore, novel analogs of TQ with lower IC(50) are highly desirable.
METHODS: We have synthesized a series of 27 new analogs of TQ by modifications at the carbonyl sites or the benzenoid sites using single pot synthesis and tested their biological activity in PC cells.
RESULTS: Among these compounds, TQ-2G, TQ-4A1 and TQ-5A1 (patent pending) were found to be more potent than TQ in terms of inhibition of cell growth, induction of apoptosis and modulation of transcription factor-NF-kappaB. We also found that our novel analogs were able to sensitize gemcitabine and oxaliplatin-induced apoptosis in MiaPaCa-2 (gemcitabine resistant) PC cells, which was associated with down-regulation of Bcl-2, Bcl-xL, survivin, XIAP, COX-2 and the associated Prostaglandin E2.
CONCLUSION: From our results, we conclude that three of our novel TQ analogs warrant further investigation against PC, especially in combination with conventional chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20422266      PMCID: PMC3093961          DOI: 10.1007/s11095-010-0145-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  33 in total

1.  In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone.

Authors:  Ahmed M Shoieb; Mona Elgayyar; Paul S Dudrick; John L Bell; Patricia K Tithof
Journal:  Int J Oncol       Date:  2003-01       Impact factor: 5.650

2.  Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells.

Authors:  Hermann Lage; Manfred Dietel
Journal:  J Cancer Res Clin Oncol       Date:  2002-06-26       Impact factor: 4.553

Review 3.  Using chemopreventive agents to enhance the efficacy of cancer therapy.

Authors:  Fazlul H Sarkar; Yiwei Li
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

4.  Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.

Authors:  Shadan Ali; Basil F El-Rayes; Fazlul H Sarkar; Philip A Philip
Journal:  Mol Cancer Ther       Date:  2005-12       Impact factor: 6.261

Review 5.  Pancreatic cancer: pathogenesis, prevention and treatment.

Authors:  Fazlul H Sarkar; Sanjeev Banerjee; Yiwei Li
Journal:  Toxicol Appl Pharmacol       Date:  2006-11-11       Impact factor: 4.219

6.  COX-2 overexpression increases motility and invasion of breast cancer cells.

Authors:  Balraj Singh; Jacob A Berry; Angela Shoher; Vijay Ramakrishnan; Anthony Lucci
Journal:  Int J Oncol       Date:  2005-05       Impact factor: 5.650

7.  Reduced risk of bone metastasis for patients with breast cancer who use COX-2 inhibitors.

Authors:  Matias E Valsecchi; Sherry C Pomerantz; Rebecca Jaslow; William Tester
Journal:  Clin Breast Cancer       Date:  2009-11       Impact factor: 3.225

8.  COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome.

Authors:  Aziza Nassar; Anu Radhakrishnan; Isabel A Cabrero; George Cotsonis; Cynthia Cohen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2007-09

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer.

Authors:  Ahmed O Kaseb; Kannagi Chinnakannu; Di Chen; Arun Sivanandam; Sheela Tejwani; Mani Menon; Q Ping Dou; G Prem-Veer Reddy
Journal:  Cancer Res       Date:  2007-08-15       Impact factor: 12.701

View more
  24 in total

Review 1.  Review on molecular and therapeutic potential of thymoquinone in cancer.

Authors:  Sanjeev Banerjee; Subhash Padhye; Asfar Azmi; Zhiwei Wang; Philip A Philip; Omer Kucuk; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

2.  Differential protection of black-seed oil on econucleotidase, cholinesterases and aminergic catabolizing enzyme in haloperidol-induced neuronal damage of male rats.

Authors:  Jacob K Akintunde; C Abigail Irechukwu
Journal:  Ther Adv Drug Saf       Date:  2016-07-22

Review 3.  Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer.

Authors:  Muzafar A Macha; Shiv Ram Krishn; Rahat Jahan; Kasturi Banerjee; Surinder K Batra; Maneesh Jain
Journal:  Cancer Treat Rev       Date:  2015-01-14       Impact factor: 12.111

4.  Thymoquinone inhibits proliferation and invasion of human nonsmall-cell lung cancer cells via ERK pathway.

Authors:  Jing Yang; Xiang-ru Kuang; Ping-tian Lv; Xi-xin Yan
Journal:  Tumour Biol       Date:  2014-09-20

Review 5.  MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma.

Authors:  Shailendra K Gautam; Sushil Kumar; Andrew Cannon; Bradley Hall; Rakesh Bhatia; Mohd Wasim Nasser; Sidharth Mahapatra; Surinder K Batra; Maneesh Jain
Journal:  Expert Opin Ther Targets       Date:  2017-05-29       Impact factor: 6.902

6.  In silico elucidation of the interactions of thymoquinone analogues with phosphatase and tensin homolog (PTEN).

Authors:  Leila Hokmabady; Najmeh Fani
Journal:  J Mol Model       Date:  2022-09-17       Impact factor: 2.172

7.  Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells.

Authors:  Getinet M Adinew; Samia S Messeha; Equar Taka; Ramesh B Badisa; Lovely M Antonie; Karam F A Soliman
Journal:  Nutrients       Date:  2022-05-19       Impact factor: 6.706

Review 8.  The Role of Nutraceuticals in Pancreatic Cancer Prevention and Therapy: Targeting Cellular Signaling, MicroRNAs, and Epigenome.

Authors:  Yiwei Li; Vay Liang W Go; Fazlul H Sarkar
Journal:  Pancreas       Date:  2015-01       Impact factor: 3.327

9.  RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients.

Authors:  Viviane P Muniz; Ryan W Askeland; Xuefeng Zhang; Sara M Reed; Van S Tompkins; Jussara Hagen; Bradley D McDowell; Anna Button; Brian J Smith; Jamie A Weydert; James J Mezhir; Dawn E Quelle
Journal:  Genes Cancer       Date:  2013-07

10.  Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo.

Authors:  Syed H Jafri; Jonathan Glass; Runhua Shi; Songlin Zhang; Misty Prince; Heather Kleiner-Hancock
Journal:  J Exp Clin Cancer Res       Date:  2010-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.